[go: up one dir, main page]

WO2010118367A3 - Antiviral pyrimidines - Google Patents

Antiviral pyrimidines Download PDF

Info

Publication number
WO2010118367A3
WO2010118367A3 PCT/US2010/030598 US2010030598W WO2010118367A3 WO 2010118367 A3 WO2010118367 A3 WO 2010118367A3 US 2010030598 W US2010030598 W US 2010030598W WO 2010118367 A3 WO2010118367 A3 WO 2010118367A3
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
infection
pyrimidines
pyrazolopyrimtdines
virus
Prior art date
Application number
PCT/US2010/030598
Other languages
French (fr)
Other versions
WO2010118367A2 (en
Inventor
Amy Qi Han
Eric Wang
Carla Gauss
Walter Xie
Glen Coburn
Jean-Marc Demuys
Original Assignee
Progenics Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Progenics Pharmaceuticals, Inc. filed Critical Progenics Pharmaceuticals, Inc.
Publication of WO2010118367A2 publication Critical patent/WO2010118367A2/en
Publication of WO2010118367A3 publication Critical patent/WO2010118367A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/553—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with halogen atoms or nitro radicals directly attached to ring carbon atoms, e.g. fluorouracil
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Disclosed herein are novel compounds comprising substituted pyrimidines, pyrazolopyrimtdines, and imidazolopyrimidines, the syntheses thereof, and compositions thereof, including pharmaceutical compositions, comprising the novel pyrimidines, pyrazolopyrimtdines, imidazolpyrimidines and related compounds. Such compounds function to inhibit entry of viruses of the Flaviviridae family, including Hepatitis C virus (HCV), into cells that are susceptible to virus infection. These compounds are useful for the treatment, therapy and/or prophylaxis of viral diseases and infection, including HCV infection.
PCT/US2010/030598 2009-04-10 2010-04-09 Antiviral pyrimidines WO2010118367A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16832309P 2009-04-10 2009-04-10
US61/168,323 2009-04-10

Publications (2)

Publication Number Publication Date
WO2010118367A2 WO2010118367A2 (en) 2010-10-14
WO2010118367A3 true WO2010118367A3 (en) 2011-03-10

Family

ID=42936895

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/030598 WO2010118367A2 (en) 2009-04-10 2010-04-09 Antiviral pyrimidines

Country Status (1)

Country Link
WO (1) WO2010118367A2 (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8476282B2 (en) 2008-11-03 2013-07-02 Intellikine Llc Benzoxazole kinase inhibitors and methods of use
US8637542B2 (en) 2008-03-14 2014-01-28 Intellikine, Inc. Kinase inhibitors and methods of use
US8993580B2 (en) 2008-03-14 2015-03-31 Intellikine Llc Benzothiazole kinase inhibitors and methods of use
US9096611B2 (en) 2008-07-08 2015-08-04 Intellikine Llc Kinase inhibitors and methods of use
US9295673B2 (en) 2011-02-23 2016-03-29 Intellikine Llc Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof
US9359349B2 (en) 2007-10-04 2016-06-07 Intellikine Llc Substituted quinazolines as kinase inhibitors
US9718825B2 (en) 2013-03-13 2017-08-01 Sanofi N-(4-(azaindazol-6-yl)-phenyl)-sulfonamides and their use as pharmaceuticals
US11730736B2 (en) 2017-11-06 2023-08-22 Rapt Therapeutics, Inc. Anticancer agents

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104945420A (en) 2009-06-29 2015-09-30 因塞特公司 Pyrimidinones as PI3K inhibitors
US8445490B2 (en) 2009-10-14 2013-05-21 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US8586584B2 (en) 2009-10-14 2013-11-19 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
WO2011075643A1 (en) 2009-12-18 2011-06-23 Incyte Corporation Substituted heteroaryl fused derivatives as pi3k inhibitors
CA2796311A1 (en) 2010-04-14 2011-10-20 Incyte Corporation Fused derivatives as pi3k.delta. inhibitors
WO2011139513A1 (en) 2010-05-04 2011-11-10 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis c
WO2011163195A1 (en) 2010-06-21 2011-12-29 Incyte Corporation Fused pyrrole derivatives as pi3k inhibitors
US8765944B2 (en) 2010-08-19 2014-07-01 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
WO2012087881A1 (en) 2010-12-20 2012-06-28 Incyte Corporation N-(1-(substituted-phenyl)ethyl)-9h-purin-6-amines as pi3k inhibitors
WO2012125629A1 (en) 2011-03-14 2012-09-20 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors
WO2012135009A1 (en) 2011-03-25 2012-10-04 Incyte Corporation Pyrimidine-4,6-diamine derivatives as pi3k inhibitors
US8933066B2 (en) 2011-04-14 2015-01-13 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
SG194549A1 (en) 2011-04-21 2013-12-30 Origenis Gmbh Pyrazolo [4, 3-d] pyrimidines useful as kinase inhibitors
TWI717002B (en) 2011-09-02 2021-01-21 美商英塞特控股公司 Heterocyclylamines as pi3k inhibitors
CN103814030A (en) 2011-09-22 2014-05-21 辉瑞大药厂 Pyrrolopyrimidine and purine derivatives
US8629150B2 (en) 2011-09-28 2014-01-14 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US8697706B2 (en) 2011-10-14 2014-04-15 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US8916702B2 (en) 2012-02-06 2014-12-23 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
AR090548A1 (en) 2012-04-02 2014-11-19 Incyte Corp BICYCLIC AZAHETEROCICLOBENCILAMINS AS PI3K INHIBITORS
CN104540830A (en) * 2012-06-07 2015-04-22 霍夫曼-拉罗奇有限公司 Pyrazolopyrimidone and pyrazolopyridone inhibitors of tankyrase
CN102827085A (en) * 2012-09-17 2012-12-19 符爱清 Preparation method for 2,4,5-trichloropyrimidine compound
CN102952086B (en) * 2012-09-28 2013-08-28 天津科创医药中间体技术生产力促进有限公司 Preparation method of 2-morpholinyl-substituted pyrimidine compounds
CN102887860B (en) * 2012-09-29 2015-07-01 上海泰坦科技有限公司 Preparation method of 4-chloro-6-trifluoromethylpyrimidine type compound
WO2014062636A1 (en) 2012-10-18 2014-04-24 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis c
WO2014060112A1 (en) * 2012-10-19 2014-04-24 Origenis Gmbh Pyrazolo[4,3-d]pyrimidines as kinase inhibitors
UA111687C2 (en) 2012-11-08 2016-05-25 Пфайзер Інк. HETEROOROMATIC COMPOUNDS AS DAMAMIN D1 LIGANDS
CA2893704C (en) * 2012-12-20 2020-12-15 Ucb Biopharma Sprl Therapeutically active pyrazolo-pyrimidine derivatives as inhibitors of phosphatidyl-inositol-4-kinase iiib (pi4kiiib) activity
EP2953953B1 (en) 2013-02-07 2017-11-15 Bristol-Myers Squibb Company Macrocyclic molecules as hcv entry inhibitors
JP2016507560A (en) 2013-02-07 2016-03-10 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Macrocyclic compounds as HCV entry inhibitors
WO2014135507A1 (en) * 2013-03-07 2014-09-12 F. Hoffmann-La Roche Ag Novel pyrazol derivatives
JP2016510746A (en) 2013-03-07 2016-04-11 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Compounds for the treatment of hepatitis C
SG11201509029PA (en) 2013-05-02 2015-12-30 Hoffmann La Roche Pyrrolo[2,3-d]pyrimidine derivatives as cb2 receptor agonists
JP6513636B2 (en) 2013-05-02 2019-05-15 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Purine Derivatives as CB2 Receptor Agonists
WO2015005491A1 (en) 2013-07-12 2015-01-15 国立大学法人京都大学 Method for screening substance capable of inhibiting abnormal splicing causative of onset or progress of disease
CA2927560A1 (en) * 2013-10-18 2015-04-23 Indiana University Research And Technology Corporation Hepatitis b viral assembly effectors
UA115388C2 (en) 2013-11-21 2017-10-25 Пфайзер Інк. 2,6-substituted purine derivatives and their use in the treatment of proliferative disorders
AU2015217152A1 (en) * 2014-02-11 2016-08-11 Mitokinin, Inc. Compositions and methods using the same for treatment of neurodegenerative and mitochondrial disease
CN106232118A (en) 2014-04-25 2016-12-14 辉瑞大药厂 Heteroaromatic compounds and their use as dopamine D1 ligands
WO2015162518A1 (en) 2014-04-25 2015-10-29 Pfizer Inc. Heteroaromatic compounds and their use as dopamine d1 ligands
WO2015191677A1 (en) 2014-06-11 2015-12-17 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors
TW202204345A (en) 2015-01-16 2022-02-01 美商通用醫院公司 COMPOUNDS FOR IMPROVING mRNA SPLICING
HRP20210036T1 (en) 2015-02-27 2021-03-05 Incyte Corporation Salts of pi3k inhibitor and processes for their preparation
WO2016168619A1 (en) 2015-04-17 2016-10-20 Indiana University Research And Technology Corporation Hepatitis b viral assembly effectors
US9988401B2 (en) 2015-05-11 2018-06-05 Incyte Corporation Crystalline forms of a PI3K inhibitor
US9732097B2 (en) 2015-05-11 2017-08-15 Incyte Corporation Process for the synthesis of a phosphoinositide 3-kinase inhibitor
US10280164B2 (en) 2016-09-09 2019-05-07 Incyte Corporation Pyrazolopyridone compounds and uses thereof
US20180072741A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyrimidine compounds and uses thereof
WO2018049214A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
EP3510032B1 (en) 2016-09-09 2022-07-06 Incyte Corporation Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
CN116854693A (en) * 2016-09-30 2023-10-10 阿沙纳生物科学公司 P2X 3 And/or P2X 2/3 Compounds and methods
US20180228786A1 (en) 2017-02-15 2018-08-16 Incyte Corporation Pyrazolopyridine compounds and uses thereof
US20200113907A1 (en) 2017-02-20 2020-04-16 Kyoto University Pharmaceutical composition and treatment method for genetic disease associated with splicing abnormalities
CN107383014B (en) * 2017-06-21 2019-04-30 南方医科大学 A kind of 1H-pyrazolo[3,4-d]pyrimidine compound and its preparation method and application
WO2018237145A1 (en) 2017-06-21 2018-12-27 Mitokinin, Inc. COMPOSITIONS AND METHODS USING THEM FOR THE TREATMENT OF NEURODEGENERATIVE AND MITOCHONDRIAL DISEASE
CN109384782A (en) 2017-08-04 2019-02-26 厦门大学 Substituted five-membered and six-membered heterocyclic compound, its preparation method, pharmaceutical combination and use thereof
WO2019051199A1 (en) 2017-09-08 2019-03-14 Incyte Corporation 6-cyano-indazole compounds as hematopoietic progenitor kinase 1 (hpk1) modulators
US10745388B2 (en) 2018-02-20 2020-08-18 Incyte Corporation Indazole compounds and uses thereof
US10752635B2 (en) 2018-02-20 2020-08-25 Incyte Corporation Indazole compounds and uses thereof
WO2019164846A1 (en) 2018-02-20 2019-08-29 Incyte Corporation N-(phenyl)-2-(phenyl)pyrimidine-4-carboxamide derivatives and related compounds as hpk1 inhibitors for treating cancer
US11299473B2 (en) 2018-04-13 2022-04-12 Incyte Corporation Benzimidazole and indole compounds and uses thereof
MA52761A (en) 2018-06-01 2021-04-14 Incyte Corp DOSAGE REGIMEN FOR THE TREATMENT OF PI3K-RELATED DISORDERS
US10899755B2 (en) 2018-08-08 2021-01-26 Incyte Corporation Benzothiazole compounds and uses thereof
EP3856348B1 (en) 2018-09-25 2024-01-03 Incyte Corporation Pyrazolo[4,3-d]pyrimidine compounds as alk2 and/or fgfr modulators
WO2020063636A1 (en) * 2018-09-27 2020-04-02 苏州锐明新药研发有限公司 Pyrazolopyrimidine compound and preparation method and use thereof in preparation of anti-cancer drug
CN110698432B (en) * 2018-11-07 2023-02-03 中国医学科学院医药生物技术研究所 Benzyl piperazine compound, preparation method thereof and application thereof in antivirus
CN111170992B (en) * 2018-11-12 2021-05-14 新发药业有限公司 Preparation method of 5, 6-dihydropyridine-2 (1H) -ketone derivative
EP3890715A4 (en) * 2018-12-04 2023-03-29 The Board Of Regents Of The University Of Texas System ANTI-ADENOMATOUS POLYPOSIS COLI (APC) THERAPEUTICS FOR THE TREATMENT OF CANCER
US12398140B2 (en) 2019-02-13 2025-08-26 Ptc Therapeutics, Inc. Substituted pyrrolo [2,3-d]pyrimidines for treating familial dysautonomia
EA202192170A1 (en) 2019-02-13 2021-11-15 ПиТиСи ТЕРАПЬЮТИКС, ИНК. THIENO [3,2-b] PYRIDINE-7-AMINE COMPOUNDS FOR THE TREATMENT OF FAMILY VEGETOVASCULAR DYSTONIA
BR112021012834A2 (en) * 2019-04-18 2021-09-28 Université de Liège PYRIMIDINE DERIVATIVES FOR THE PREVENTION AND TREATMENT OF GRAM-NEGATIVE BACTERIAL INFECTIONS
US11066394B2 (en) 2019-08-06 2021-07-20 Incyte Corporation Solid forms of an HPK1 inhibitor
CN110437253A (en) * 2019-08-06 2019-11-12 复旦大学 Diaryl pyrimidine and cycle compound of biphenyl contenting structure and its preparation method and application
WO2021050900A1 (en) 2019-09-13 2021-03-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Receptor tyrosine kinase inhibitors for treatment of protein kinase modulation-responsive disease or disorder
EP3800188A1 (en) 2019-10-02 2021-04-07 Bayer AG Substituted pyrazolopyrimidines as irak4 inhibitors
WO2021102600A1 (en) 2019-11-29 2021-06-03 中国医学科学院医药生物技术研究所 Benzyl piperazine compound, preparation method therefor and application thereof in antivirus
JP2023508978A (en) * 2019-12-23 2023-03-06 サンフォード バーナム プレビス メディカル ディスカバリー インスティテュート Ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) modulators and uses thereof
CA3184151A1 (en) * 2020-06-29 2022-01-06 Chris Murphy Probenecid compounds for the treatment of inflammasome-mediated lung disease
CN111732575B (en) * 2020-08-03 2020-12-11 北京鑫开元医药科技有限公司 A kind of N-(3-(pyrimidin-2-yl)phenyl)benzenesulfonamide derivatives, pharmaceutical composition, preparation method and application
JP2023552632A (en) * 2020-12-11 2023-12-18 イルドン ファーマシューティカル カンパニー リミテッド Novel compounds as dual androgen receptor and phosphodiesterase inhibitors
CN113292452B (en) * 2021-06-01 2023-03-24 山东京博生物科技有限公司 Synthetic method of cyanoacetamide
CN113979945A (en) * 2021-11-15 2022-01-28 湖北理工学院 A new method for preparing 3-aminopyrazole-4-carboxamide hemisulfate
WO2024168106A2 (en) * 2023-02-09 2024-08-15 Caraway Therapeutics, Inc. Modulators of trpml, their compositions and methods of use
WO2024168104A2 (en) * 2023-02-09 2024-08-15 Caraway Therapeutics, Inc. Modulators of trpml, their compositions and methods of use

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5478830A (en) * 1992-05-29 1995-12-26 The Du Pont Merck Pharmaceutical Company Fused-ring heterocycles for the treatment of atherosclerosis
JP2004506737A (en) * 2000-08-18 2004-03-04 アグーロン　ファーマシューティカルズ，インコーポレイテッド Pyrazole compounds, pharmaceutical compositions, and methods of modulating or inhibiting ELAB or HADH2 activity
WO2005121107A1 (en) * 2004-06-09 2005-12-22 F. Hoffmann-La Roche Ag Pyrazolo pyrimidines
WO2006132460A1 (en) * 2005-06-10 2006-12-14 Dong-A Pharmaceutical.Co., Ltd. Agent for the prevention and treatment of liver diseases containing pyrazolopyrimidine derivative

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5478830A (en) * 1992-05-29 1995-12-26 The Du Pont Merck Pharmaceutical Company Fused-ring heterocycles for the treatment of atherosclerosis
JP2004506737A (en) * 2000-08-18 2004-03-04 アグーロン　ファーマシューティカルズ，インコーポレイテッド Pyrazole compounds, pharmaceutical compositions, and methods of modulating or inhibiting ELAB or HADH2 activity
WO2005121107A1 (en) * 2004-06-09 2005-12-22 F. Hoffmann-La Roche Ag Pyrazolo pyrimidines
WO2006132460A1 (en) * 2005-06-10 2006-12-14 Dong-A Pharmaceutical.Co., Ltd. Agent for the prevention and treatment of liver diseases containing pyrazolopyrimidine derivative

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9359349B2 (en) 2007-10-04 2016-06-07 Intellikine Llc Substituted quinazolines as kinase inhibitors
US8637542B2 (en) 2008-03-14 2014-01-28 Intellikine, Inc. Kinase inhibitors and methods of use
US8993580B2 (en) 2008-03-14 2015-03-31 Intellikine Llc Benzothiazole kinase inhibitors and methods of use
US9637492B2 (en) 2008-03-14 2017-05-02 Intellikine Llc Benzothiazole kinase inhibitors and methods of use
US9096611B2 (en) 2008-07-08 2015-08-04 Intellikine Llc Kinase inhibitors and methods of use
US9828378B2 (en) 2008-07-08 2017-11-28 Intellikine Llc Kinase inhibitors and methods of use
US8476282B2 (en) 2008-11-03 2013-07-02 Intellikine Llc Benzoxazole kinase inhibitors and methods of use
US8476431B2 (en) 2008-11-03 2013-07-02 Itellikine LLC Benzoxazole kinase inhibitors and methods of use
US9295673B2 (en) 2011-02-23 2016-03-29 Intellikine Llc Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof
US9718825B2 (en) 2013-03-13 2017-08-01 Sanofi N-(4-(azaindazol-6-yl)-phenyl)-sulfonamides and their use as pharmaceuticals
US11730736B2 (en) 2017-11-06 2023-08-22 Rapt Therapeutics, Inc. Anticancer agents

Also Published As

Publication number Publication date
WO2010118367A2 (en) 2010-10-14

Similar Documents

Publication Publication Date Title
WO2010118367A3 (en) Antiviral pyrimidines
WO2009091388A3 (en) Triazines and related compounds having antiviral activity, compositions and methods thereof
WO2011041713A3 (en) Piperazinyl antiviral agents
MX2010009563A (en) Chemical compounds having antiviral activity against dengue virus and other flaviviruses.
EP2853531A3 (en) Antiviral compounds
PH12012502343A1 (en) Antiviral drugs for treatment or prevention of dengue infection
WO2008133753A3 (en) Anti-viral compounds
EA201390538A1 (en) ANTI-VIRUS COMPOUNDS
EA201000556A1 (en) SPYROPYRROLIDINES AND THEIR APPLICATION TO FIGHT AGAINST INFECTING THROUGH HCV (HEPATITIS C VIRUS) AND HIV (HUMAN IMMUNODEFICIENUS VIRUS)
WO2010081082A3 (en) Phosphoramidate derivatives of guanosine nucleoside compounds for treatment of viral infections
IL195025A (en) Cyclopropyl fused indolobenzazepine derivatives and pharmaceutical compositions comprising the same as anti-hcv medicament
TN2012000264A1 (en) Hepatitis c virus inhibitors
TN2012000214A1 (en) Hepatitis c virus inhibitors
MX2011008045A (en) Hepatitis c virus inhibitors.
MY152971A (en) Hepatitis c virus inhibitors
WO2012092484A3 (en) Substituted purine nucleosides, phosphoroamidate and phosphorodiamidate derivatives for treatment of viral infections
TW200720285A (en) Nucleoside compounds for treating viral infections
ATE475660T1 (en) ANTIVIRAL COMPOUNDS
WO2008021936A3 (en) Hepatitis c virus inhibitors
WO2007041487A3 (en) Viral peptides and their use to inhibit viral infections against viruses of the flaviridae family
WO2011106992A8 (en) Inhibitors of hepatitis c virus ns5b polymerase
MX2009009473A (en) Compounds for the treatment of hepatitis c.
WO2010055164A3 (en) Isoquinolone derivatives as inhibitors of plavivirus replication
CA2862755A1 (en) Antiviral compounds with a dibenzooxaheterocycle moiety
WO2009094190A3 (en) Methods of treating viral infections

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10762525

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10762525

Country of ref document: EP

Kind code of ref document: A2